These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22173061)

  • 1. PTLD treatment: a step forward, a long way to go.
    Montserrat E
    Lancet Oncol; 2012 Feb; 13(2):120-1. PubMed ID: 22173061
    [No Abstract]   [Full Text] [Related]  

  • 2. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of PTLD with rituximab or chemotherapy.
    Elstrom RL; Andreadis C; Aqui NA; Ahya VN; Bloom RD; Brozena SC; Olthoff KM; Schuster SJ; Nasta SD; Stadtmauer EA; Tsai DE
    Am J Transplant; 2006 Mar; 6(3):569-76. PubMed ID: 16468968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EBV and posttransplantation lymphoproliferative disease: what to do?
    Zimmermann H; Trappe RU
    Hematology Am Soc Hematol Educ Program; 2013; 2013():95-102. PubMed ID: 24319169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone therapy for posttransplantation lymphoproliferative disease in pediatric patients undergoing solid organ transplantation.
    Suryanarayan K; Natkunam Y; Berry G; Bangs CD; Cherry A; Dahl G
    J Pediatr Hematol Oncol; 2001 Oct; 23(7):452-5. PubMed ID: 11878581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant.
    Burns DM; Clesham K; Hodgson YA; Fredrick L; Haughton J; Lannon M; Hussein H; Shin JS; Hollows RJ; Robinson L; Byrne C; McNamara C; Vydianath B; Lennard AL; Fields P; Johnson R; Wright J; Fox CP; Cwynarski K; Chaganti S
    Transplantation; 2020 Dec; 104(12):2582-2590. PubMed ID: 33104308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders.
    Podoltsev N; Zhang B; Yao X; Bustillo I; Deng Y; Cooper DL
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):716-20. PubMed ID: 24035715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
    Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
    Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
    Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
    Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases.
    Patel H; Vogl DT; Aqui N; Shaked A; Olthoff K; Markmann J; Reddy R; Stadtmauer EA; Schuster S; Tsai DE
    Leuk Lymphoma; 2007 May; 48(5):885-91. PubMed ID: 17487731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DA-EPOCH-R for post-transplant lymphoproliferative disorders.
    DeStefano CB; Malkovska V; Rafei H; Shenoy A; Fitzpatrick K; Aggarwal A; Catlett JP
    Eur J Haematol; 2017 Sep; 99(3):283-285. PubMed ID: 28509395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
    Trappe RU; Dierickx D; Zimmermann H; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Salles G; Kliem V; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S
    J Clin Oncol; 2017 Feb; 35(5):536-543. PubMed ID: 27992268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective.
    Rubinstein JD; Shah R; Breese EH; Burns KC; Mangino JL; Norris RE; Lee L; Mizukawa B; O'Brien MM; Phillips CL; Perentesis JP; Pommert L; Absalon MJ
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29126. PubMed ID: 34019326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplant lymphoproliferative disorder in children: recent outcomes and response to dual rituximab/low-dose chemotherapy combination.
    Gupta S; Fricker FJ; González-Peralta RP; Slayton WB; Schuler PM; Dharnidharka VR
    Pediatr Transplant; 2010 Nov; 14(7):896-902. PubMed ID: 20642490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extreme hypercalcemia in a kidney transplant recipient.
    Demir E; Karaoglan C; Yegen G; Sair B; Yazici H; Turkmen A; Sever MS
    CEN Case Rep; 2018 Nov; 7(2):229-233. PubMed ID: 29705974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):9-11. PubMed ID: 25768994
    [No Abstract]   [Full Text] [Related]  

  • 17. Polymyositis following autologous haematopoietic stem cell transplantation.
    Hedermann G; Marquart HV; Vissing J
    Scand J Rheumatol; 2016 Oct; 45(5):429-31. PubMed ID: 27050436
    [No Abstract]   [Full Text] [Related]  

  • 18. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation.
    Choquet S; Trappe R; Leblond V; Jäger U; Davi F; Oertel S
    Haematologica; 2007 Feb; 92(2):273-4. PubMed ID: 17296588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of post-transplant lymphoproliferative disease with rituximab].
    Jiang YJ; Wang X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):852-6. PubMed ID: 24989308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate-associated lymphoproliferative disorder arising in the retromolar triangle and lung of a patient with rheumatoid arthritis.
    Kudoh M; Harada H; Matsumoto K; Sato Y; Omura K; Ishii Y
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Oct; 118(4):e105-10. PubMed ID: 24811204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.